Rezolute, Inc. (RZLT)
4.87
+0.23
(+4.96%)
USD |
NASDAQ |
Oct 09, 16:00
4.86
-0.01
(-0.21%)
After-Hours: 20:00
Rezolute EPS Diluted (Quarterly) : -0.1961 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1961 |
| March 31, 2026 | -0.1554 |
| December 31, 2025 | -0.2196 |
| September 30, 2025 | -0.1755 |
| June 30, 2025 | -0.2585 |
| March 31, 2025 | -0.2701 |
| December 31, 2024 | -0.2249 |
| September 30, 2024 | -0.2205 |
| June 30, 2024 | -0.4399 |
| March 31, 2024 | -0.3356 |
| December 31, 2023 | -0.2706 |
| September 30, 2023 | -0.2825 |
| June 30, 2023 | -0.2476 |
| March 31, 2023 | -0.3048 |
| December 31, 2022 | -0.2637 |
| September 30, 2022 | -0.1946 |
| June 30, 2022 | -0.3717 |
| March 31, 2022 | -0.651 |
| December 31, 2021 | -0.8031 |
| September 30, 2021 | -0.9205 |
| June 30, 2021 | -0.7771 |
| March 31, 2021 | -0.4424 |
| December 31, 2020 | -0.8822 |
| September 30, 2020 | -0.617 |
| June 30, 2020 | -0.6045 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.859 |
| December 31, 2019 | -1.136 |
| September 30, 2019 | -0.939 |
| June 30, 2019 | -0.748 |
| March 31, 2019 | -17.82 |
| December 31, 2018 | -3.350 |
| September 30, 2018 | -2.706 |
| June 30, 2018 | -10.50 |
| March 31, 2018 | -4.594 |
| December 31, 2017 | -5.50 |
| September 30, 2017 | -6.50 |
| June 30, 2017 | -6.458 |
| March 31, 2017 | -6.378 |
| December 31, 2016 | -6.00 |
| September 30, 2016 | -5.50 |
| June 30, 2016 | -19.00 |
| March 31, 2016 | -7.50 |
| December 31, 2015 | -8.50 |
| September 30, 2015 | -7.00 |
| June 30, 2015 | -6.244 |
| March 31, 2015 | -7.00 |
| December 31, 2014 | -8.00 |
| September 30, 2014 | -6.00 |
| June 30, 2014 | -5.542 |
| March 31, 2014 | -228.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.033 |
| Avalo Therapeutics, Inc. | -0.8339 |
| Opus Genetics, Inc. | -0.139 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -20.49M |
| Total Expenses (Quarterly) | 20.49M |
| Enterprise Value | 362.63M |
| Earnings Yield | -15.33% |
| Normalized Earnings Yield | -15.40 |